Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of EP395 in Healthy Volunteers
NCT04819854Phase 1Completed
- Sponsor
- EpiEndo Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in chronic obstructive pulmonary disease (COPD) comparing EP395 with Placebo (2 arms). Primary endpoints: Safety and Tolerability at day 42, Electrocardiogram at day 42 and 4 more. Started Apr 2021; status: completed.
02
Drugs
glasmacinal
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04819854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819854.